Evidence map›Paper›PMID 37753628›Full record

ArticleMagnetic resonance in medicine2024

Human prostate MRI at ultrahigh-performance gradient: A feasibility study.

Ante Zhu, Matthew Tarasek, Yihe Hua, Eric Fiveland, Stephan E Maier, Yousef Mazaheri, Maggie Fung, Carl-Fredrik Westin, Desmond T B Yeo, Filip Szczepankiewicz and 3 more

Open access · greenAbstract read
In one paragraph

Article in Magnetic resonance in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Engineering clinical translation of OGSE diffusion MRI.Magnetic resonance in medicine · 2025
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Ante ZhuGE Research, Niskayuna, New York, USA.ORCID 0000-0001-6251-2341
Matthew TarasekGE Research, Niskayuna, New York, USA.ORCID 0000-0001-6893-5230
Yihe HuaGE Research, Niskayuna, New York, USA.
Eric FivelandGE Research, Niskayuna, New York, USA.
Stephan E MaierBrigham and Women's Hospital, Boston, Massachusetts, USA.
Yousef MazaheriMemorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0002-8493-1608
Maggie FungGE Healthcare, New York, New York, USA.
Carl-Fredrik WestinBrigham and Women's Hospital, Boston, Massachusetts, USA.
Desmond T B YeoGE Research, Niskayuna, New York, USA.
Filip SzczepankiewiczMedical Radiation Physics, Clinical Sciences Lund, Lund University, Lund, Sweden.
Clare TempanyBrigham and Women's Hospital, Boston, Massachusetts, USA.
Oguz AkinMemorial Sloan Kettering Cancer Center, New York, New York, USA.
Thomas K F FooGE Research, Niskayuna, New York, USA.
GE Global Research (United States) · USBrigham and Women's Hospital · USMemorial Sloan Kettering Cancer Center · USGeneral Electric (Spain) · ESLund University · SE

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
TRD 3 - Enabling Technologies for Intraprocedural GuidanceP41EB028741 · NIBIB · BRIGHAM AND WOMEN'S HOSPITAL · PI Oliver Jonas · 2021 to 2026
$10.7M
Enabling clinical tissue microstructure imaging as a diagnostic tool in wide-bore 3T MRIU01EB034313 · NIBIB · GENERAL ELECTRIC GLOBAL RESEARCH CTR · PI Oguz Akin, Thomas K Foo · 2023 to 2026
$4.1M
Pilot study of an implantable microdevice to test multiple drug responses in prostate cancer patientsR01CA232174 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI HATA, NOBUHIKO, JONAS, OLIVER · 2019 to 2023
$3.4M
Implantable microdevices with integrated optical imaging for high-throughput in situ tumor response and drug sensitivity measurementR37CA224144 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI JONAS, OLIVER · 2018 to 2023
$2.4M
Development of Methods for a Simplified and Reliable Prostate Cancer MRI ExamR01CA241817 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI MAIER, STEPHAN E · 2020 to 2025
$2.3M
Training in Image Guidance, Precision Diagnosis and TherapyT32EB025823 · NIBIB · BRIGHAM AND WOMEN'S HOSPITAL · PI Fiona Fennessy, Lauren Jean O'Donnell · 2019 to 2026
$1.5M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA232174NCI NIH HHS R01 CA241817NCI NIH HHS R37 CA224144NIBIB NIH HHS P41 EB028741NIBIB NIH HHS T32 EB025823NIBIB NIH HHS U01 EB034313NIH HHS P30 CA008748NIH HHS P41 EB028741NIH HHS R01 CA232174NIH HHS R01 CA241817NIH HHS T32 EB025823NIH HHS U01 EB034313
6 · The paper itself

Abstract

purposeTo demonstrate the technical feasibility and the value of ultrahigh-performance gradient in imaging the prostate in a 3T MRI system.

methodsIn this local institutional review board-approved study, prostate MRI was performed on 4 healthy men. Each subject was scanned in a prototype 3T MRI system with a 42-cm inner-diameter gradient coil that achieves a maximum gradient amplitude of 200 mT/m and slew rate of 500 T/m/s. PI-RADS V2.1-compliant axial T

resultsIn all 4 subjects (waist circumference = 81-91 cm, age = 45-65 years), no peripheral nerve stimulation sensation was reported during DWI. Reduced image distortion in the posterior peripheral zone prostate gland and higher signal intensity, such as in the surrounding muscle of high-gradient DWI, were noted.

conclusionHuman prostate MRI at simultaneously high gradient amplitude of 200 mT/m and slew rate of 500 T/m/s is feasible, demonstrating that improved gradient performance can address image distortion and T

Indexed as

Magnetic Resonance ImagingProstatic NeoplasmsAgedDiffusion Magnetic Resonance ImagingEcho-Planar ImagingFeasibility StudiesHumansMaleMiddle AgedProstateReproducibility of Resultsdiffusion MRIecho timeimage distortionprostateultrahigh-performance gradient

Identifiers

PMID37753628
PMCPMC10841413
OpenAlexW4387078053

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.